Incyte Corp. (INCY) disclosed Monday morning that it was informed last week of a case of progressive multifocal leukoencephalopathy in a 75 year old male patient from the United Kingdom with myelofibrosis treated with ruxolitinib.
Incyte gapped open sharply lower Monday and is now down 2.28 at $22.56 on above average volume. The stock has fallen to nearly a 2-week low.
For comments and feedback: editorial@rttnews.com